1. Pink Sheet
  2. >>Geography

EU Acknowledges Demand For Psychedelic Drug Development Progress: One Million Signatures Now Needed

 
• By Neena Brizmohun

The European Commission has registered a European citizens' initiative that explains how the EU can foster equitable, timely, affordable, safe and legal access to innovative psychedelic-assisted treatments. Work towards securing the one million signatures needed for the next step is starting soon.

Evidence is growing to support the effectiveness of psychedelic-assisted therapies • Source: Shutterstock

The European Commission has officially recognized a European citizens' initiative (ECI) urging it to foster affordable and safe access to innovative psychedelic therapies for mental health disorders by implementing strategies such as offering milestone payment reward schemes for such products.

Key Takeaways

  • The European Commission has registered a European citizens' initiative, PsychedeliCare, which lays out why and how the bloc should implement measures to establish an expert consensus on standards of psychedelic therapies and improve access to EU-funded research for therapeutic applications.

Leveraging the European Medicines Agency’s PRIME (priority medicines) scheme during the development of psychedelic therapies and establishing a more predictable...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.